|
Mechanism5-HT1A receptor antagonists [+3] |
|
Originator Org.- |
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanism5-HT2A receptor agonists |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I
The purpose of this study is to investigate the effects of oral psilocybin in migraine headache. Subjects will each receive a dose of placebo and a dose of psilocybin approximately 14 days apart. Subjects will be randomized to the order of treatment and they will be randomized to receive either low or high dose psilocybin. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. This preliminary study will inform on the basic effects of psilocybin in migraine headache and inform on the design of larger, more definitive studies.
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders
The purpose of this study is to investigate the effects of an oral psilocybin pulse regimen in cluster headache. Subjects will be randomized to receive oral placebo, low dose psilocybin, or high dose psilocybin in three experimental sessions, each separated by 5 days. Subjects will maintain a headache diary prior to, during, and after the pulse regimen in order to document headache frequency and intensity before, during, and after the pulse regimen. After at least 6 months from the last experimental session, subjects may be invited for a second round, in which they will be randomized to receive either low dose or high dose psilocybin.
100 Clinical Results associated with Ceruvia Lifesciences LLC.
0 Patents (Medical) associated with Ceruvia Lifesciences LLC.
100 Deals associated with Ceruvia Lifesciences LLC.
100 Translational Medicine associated with Ceruvia Lifesciences LLC.